Companies
Accelerate Diagnostics
its Accelerate Pheno system runs rapid phenotypic antibiotic susceptibility testing directly from a positive blood culture, with clinical performance documented across multiple peer-reviewed studies.
- Country
- United States
- Ticker
- AXDX
Growth
Accelerate Pheno system
Coverage
| CN | EU | US | |
|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Revenue | $11.7 million for the year ended December 31, 2024 (2024-12-31) | last10k.com |
| Headcount | approximately 107 full-time employees worldwide (2024-12-31) | annualreports.com |
| Production site | Tucson, Arizona | annualreports.com |
| Regulatory approval | FDA de novo clearance for Accelerate Pheno system and PhenoTest BC Kit (2017) | sec.gov |
| Regulatory approval | FDA 510(k) clearance for Accelerate Arc system and BC kit (2024) | last10k.com |
| Certification | CE mark for Accelerate Pheno system and PhenoTest BC kit (2015) | sec.gov |
| Certification | CE IVDR registration for Accelerate Arc system and BC kit (2022) | sec.gov |
Independent sources: annualreports.com · last10k.com · sec.gov
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Rapid antibiotic-resistance tests | diagnostics-medtech | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.